X
Oct 08, 2021 06:48 PM (GMT+8) · EqualOcean
Financial Associated Press, October 8 - Guilin Sanjin announced that recently, Baifan Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Baifan biology"), a wholly-owned subsidiary of the company, received an audit report issued by the EU quality authorized person (QP). According to eudralex Vol 4 regulations (EU GMP) and the guiding principles of ICH, the audit covers important production links such as plant facilities, quality system, QC and pollution control. QP audit report shows: "Baifan biology has invested a lot of resources and efforts in the development of facilities and systems. The design of the facility is based on the most advanced concept of single use system, and the design of drug quality system meets international standards."